These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Prognostic value of bone marrow (18)F-FDG uptake pattern of pretreatment PET-CT in extranodal NK/T cell lymphoma].
    Author: Zhang Y, Zhou J, Wang L, Li JY, Ding CY.
    Journal: Zhonghua Zhong Liu Za Zhi; 2020 Oct 23; 42(10):885-890. PubMed ID: 33113633.
    Abstract:
    Objective: To investigate the prognostic value of bone marrow (BM) (18)F-fluorodeoxyglucose ((18)F-FDG) uptake pattern of pretreatment positron emission tomography/computed tomography (PET-CT) in extranodal NK/T cell lymphoma (ENKTL) patients. Methods: We retrospectively collected clinical data from a series of 63 ENKTL patients with stageⅡ~Ⅳ, who have received both (18)F-FDG PET-CT and bone marrow biopsy (BMB) prior to treatment. According the BM (18)F-FDG uptake pattern of PET-CT, the patients were divided into three groups: focal BM FDG uptake higher than liver (fPET+ ), diffuse BM uptake higher than liver (dPET+ ) and normal BM uptake (lower than liver) (nPET). The Kaplan-Meier method and Log-rank test were respectively used for survival analysis and univariate analysis, and COX proportional hazards model for multivariate analysis. Results: Among the 63 patients, 22 patients had nPET, 24 patients showed dPET+ , and 17 patients had fPET+ . BMB positive was found in 8 patients, and negative in 55 patients. Thirty-seven patients had disease progression or relapse, and 31 patients died. The 3-years progression free survival (3y-PFS) rates of fPET+ patients and nPET patients were 14.7% and 63.6% (P=0.006). The 3-years overall survival (3y-OS) rates were 18.8% and 64.8% (P=0.005). The 3y-PFS of dPET+ patients and nPET patients were 35.6% and 63.6% (P=0.161), 3y-OS were 47.9% and 64.8% (P=0.280). Univariate analysis showed that lactate dehydrogenase (LDH) level, Epstein-Barr virus DNA (EBV-DNA), Korean prognostic index (KPI) and BM (18)F-FDG were related with PFS and OS (all P<0.05). Multivariate analysis showed EBV-DNA and BM (18)F-FDG were independent predictors for PFS (P<0.05). EBV-DNA was also an independently predictor for OS (P<0.05). Conclusions: PET/CT-directed BM patterns are meaningful in predicting prognosis of newly diagnosed ENKTL patients. Focal BM (18)F-FDG uptake pattern is an independent predictor for PFS. 目的: 探讨初诊结外NK/T细胞淋巴瘤(ENKTL)治疗前(18)F-脱氧葡萄糖((18)F-FDG)正电子发射计算机断层扫描(PET-CT)显像中骨髓摄取形态预测预后的价值。 方法: 回顾性分析63例Ⅱ~Ⅳ期ENKTL患者的临床病理资料,全组患者治疗前均行骨髓活检和(18)F-FDG PET-CT检查。以正常肝脏组织(18)F-FDG摄取为标准,将患者分为骨髓(18)F-FDG摄取增高局灶型、弥漫型和摄取正常型。采用Kaplan-Meier法和log rank检验进行单因素生存分析,多因素生存分析采用Cox比例风险模型。 结果: 63例患者中,PET-CT显像中骨髓(18)F-FDG摄取正常型22例,骨髓(18)F-FDG摄取增高弥漫型24例,骨髓(18)F-FDG摄取增高局灶型17例。骨髓活检诊断骨髓浸润阴性55例,阳性8例。63例患者中,复发进展37例,死亡31例。骨髓(18)F-FDG摄取增高局灶型和正常型患者的3年无进展生存率分别为14.7%和63.6%(P=0.006),3年总生存率分别为18.8%和64.8%(P=0.005)。骨髓(18)F-FDG摄取增高弥漫型和正常型患者的3年无进展生存率分别为35.3%和63.6%(χ(2)=1.968,P=0.161),3年总生存率分别为47.9%和64.8%(P=0.280)。单因素生存分析结果示,乳酸脱氢酶、EB病毒(EBV)DNA、韩国预后指数、骨髓(18)F-FDG摄取形态均与患者的无进展生存和总生存有关(均P<0.05);多因素生存分析结果示,EBV-NDA、骨髓(18)F-FDG摄取形态为影响患者无进展生存的独立危险因素(均P<0.05),EBV-DNA是影响患者总生存的独立危险因素(P<0.05)。 结论: ENKTL患者治疗前(18)F-FDG PET-CT显像中骨髓摄取形态对患者预后评估具有一定的价值,骨髓(18)F-FDG摄取增高局灶型是影响患者无进展生存的独立危险因素。.
    [Abstract] [Full Text] [Related] [New Search]